This document is posted to help you gain knowledge. Please leave a comment to let me know what you think about it! Share it to your friends and learn new things together.
Transcript
Von Willebrand Disease: Recognizing a Prevalent Bleeding Disorder
Kristen Jaworski RN, BSN, CCRC Hemophilia Center of Western PA
CE Credit(s) 1.0 contact hour(s)
Faculty Disclosure Dr. Jaworski has no actual or potential conflicts of interest in relation to this program.
Learning Objectives •Define the epidemiology of Von Willebrand Disease •Describe the pathophysiology, including types, of Von Willebrand Disease •Provide an overview of the tiered treatment regimen in type I Von Willebrand Disease
Legal Disclaimer The material presented here does not necessarily reflect the views of Pharmaceutical Education Consultants (PharmCon) or the companies that support educational programming. A qualified healthcare professional should always be consulted before using any therapeutic product discussed. Participants should verify all information and data before treating patients or employing any therapies described in this educational activity.
Von Willebrand Disease: Recognizing a Prevalent Bleeding Disorder
PharmCon is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education
• Lack of function of a blood protein called von
Willebrand factor
• Von Willebrand factor works with factor VIII to
create blood clots
PharmCon is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education
• Injury
• Vessel constricts
• Endothelial cells
• VW binds to collagen at injury site
• Platelet rush to injury
• VW works as the glue
Von Willebrand Disease: Recognizing a Prevalent Bleeding Disorder
Pier M. Mannucci. Blood January 15, 2002 vol. 99 no. 2 450-456
PharmCon is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education
• Dose 20-80 units/kg • calculated based on the FVIII content of the products
• OR
• dosing based on VWF functional activity [e.g., VWF ristocetin cofactor activity (VWF:RCo)]
• Half life 8-12 hours
• IV push
Batlle, Javier. Blood Coagulation & Fibrinolysis: March 2009 - Volume 20 - Issue 2 - p 89-100
PharmCon is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education
Median values of plasma levels.VWF:RCof (circles, dash-dot lines) and FVIII:C (triangles, solid lines) (A) and of bleeding times (squares, short dash lines) (B) before and after administration of A-SD (open symbols) and A-SD/HT (closed symbols), 60 IU/kg VW...